{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-021314","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.656021+00:00","generated_at":"2026-05-22T23:45:23.794015+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Madrigal Q1 2025 revenue $137.3M from Rezdiffra; 17,000+ patients on therapy","bullets":["Net Rezdiffra sales of $137.3M in Q1 2025 vs. $0 in prior-year period as first commercial quarter.","Operating expenses $216.6M (up 42% YoY) driven by SG&A for Rezdiffra launch; R&D fell to $44.2M.","Cash, equivalents, restricted cash and marketable securities $848.1M at March 31, 2025.","Appointed David Soergel, M.D. as CMO; Jacqualyn Fouse, Ph.D. to Board of Directors.","Two-year F4c cirrhosis data from MAESTRO-NAFLD-1 accepted as EASL late-breaker (May 7–10)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-021314","json":"https://secwatch.observer/filing/0001628280-25-021314.json","markdown":"https://secwatch.observer/filing/0001628280-25-021314.md","text":"https://secwatch.observer/filing/0001628280-25-021314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025021314/0001628280-25-021314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025021314/mdgl-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T23:45:23.794015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}